3Chua K & Howden BP.Treating Gram-positive infections:vancomycin update and the whys,wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics[J].Cur Opin Infect Dis,2009,22:525-534.
4CDC.Staphylococcus aureus Resistant to Vancomycin-United States,2002[J].MMRW,2002,51(26):565-567.
5Courvalin P.Vancomycin Resistance in Gram-Positive Cocci[J].Clin Infect Dis,2006,42(S),S25-S34.
6Xiao YH,Wang J,Li Y.Bacterial resistance surveillance in China:a report from Mohnarin 2004-2005[J].Eur J Clin Microbiol Infect Dis,2008,27:697-709.
8Werner G,Coque TM,Hammerum AH,et al.Emergence and spread of vancomycin resistance among enterococcus in Europe[J].Eurosurveillance,2008,13(47):1-11.
9Jones RN.Microbiological features of vancomycin in the 21st century:minimum inhibitory concentration Creep,bactericidal/Static activity,and applied breakpoints to predict clinical outcomes or detect resistant strains[J].Clin Infect Dis,2006,42(S):S13-S24.
10Draghi DC,Moeck G,Arhin FF,et al.A Current Look at the In Vitro Activity of Oritavancin and Vancomycin against Isolates of S.aureiu from Both Europe and the US.ECCHIC,2009,poster 1673.
